Trial · NCT00865566
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participant Dropout Through Month 48 | Vaccine | 340 | Participants | ||
| Participant Dropout Through Month 48 | Placebo | 436 | Participants | ||
| Participant Dropout Prior to Unblinding | Vaccine | 99 | Participants | ||
| Participant Dropout Prior to Unblinding | Placebo | 127 | Participants | ||
| Participant Dropout After Unblinding | Vaccine | 241 | Participants | ||
| Participant Dropout After Unblinding | Placebo | 309 | Participants | ||
| HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit | Vaccine | 75 | participants | ||
| HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit | Placebo | 68 | participants | ||
| HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit | Vaccine | 49 | participants | ||
| HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit | Placebo | 46 | participants | ||
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Vaccine | None | 138 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Placebo | None | 415 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Vaccine | Mild | 723 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Placebo | Mild | 744 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Vaccine | Moderate | 370 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Placebo | Moderate | 90 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Vaccine | Severe | 22 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Placebo | Severe | 2 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Vaccine | Potentially life-threatening | 0 | Participants | |
| Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness | Placebo | Potentially life-threatening | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00865566/results